BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19221002)

  • 1. Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF.
    Khanal P; Lee KY; Kang KW; Kang BS; Choi HS
    Carcinogenesis; 2009 Apr; 30(4):682-9. PubMed ID: 19221002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
    Kim G; Khanal P; Lim SC; Yun HJ; Ahn SG; Ki SH; Choi HS
    Carcinogenesis; 2013 Feb; 34(2):341-50. PubMed ID: 23125217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of TRPM6 transcriptional activity by AP-1 in renal epithelial cells.
    Ikari A; Sanada A; Okude C; Sawada H; Yamazaki Y; Sugatani J; Miwa M
    J Cell Physiol; 2010 Mar; 222(3):481-7. PubMed ID: 19937979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.
    Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM
    Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
    Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA.
    Li J; Ma C; Huang Y; Luo J; Huang C
    Oncogene; 2003 Jan; 22(2):211-9. PubMed ID: 12527890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1.
    Nielsen C; Thastrup J; Bøttzauw T; Jäättelä M; Kallunki T
    Cancer Res; 2007 Jan; 67(1):178-85. PubMed ID: 17210697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: possible roles of AP-1.
    Okimoto T; Kohno K; Kuwano M; Gopas J; Kung HF; Ono M
    Oncogene; 1996 Apr; 12(8):1625-33. PubMed ID: 8622882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
    Dhar A; Hu J; Reeves R; Resar LM; Colburn NH
    Oncogene; 2004 May; 23(25):4466-76. PubMed ID: 15064752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.
    Kim JE; Son JE; Jang YJ; Lee DE; Kang NJ; Jung SK; Heo YS; Lee KW; Lee HJ
    J Pharmacol Exp Ther; 2011 Sep; 338(3):1013-22. PubMed ID: 21705614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.
    Jiang LQ; Feng X; Zhou W; Knyazev PG; Ullrich A; Chen Z
    Oncogene; 2006 Sep; 25(40):5495-506. PubMed ID: 16636672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
    Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
    Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C
    Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
    Watts RG; Huang C; Young MR; Li JJ; Dong Z; Pennie WD; Colburn NH
    Oncogene; 1998 Dec; 17(26):3493-8. PubMed ID: 10030673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
    Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
    J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of activator protein-1 on the effect of arginine-glycine-aspartic acid containing peptides on transforming growth factor-beta1 promoter activity.
    Ruiz-Torres MP; Perez-Rivero G; Diez-Marques ML; Griera M; Ortega R; Rodriguez-Puyol M; Rodríguez-Puyol D
    Int J Biochem Cell Biol; 2007; 39(1):133-45. PubMed ID: 16978906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts.
    Tong L; Smyth D; Kerr C; Catterall J; Richards CD
    Cell Signal; 2004 Oct; 16(10):1123-32. PubMed ID: 15240007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element.
    Manfroid I; Van de Weerdt C; Baudhuin A; Martial JA; Muller M
    Mol Cell Endocrinol; 2005 Jan; 229(1-2):127-39. PubMed ID: 15607537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PACAP and C2-ceramide generate different AP-1 complexes through a MAP-kinase-dependent pathway: involvement of c-Fos in PACAP-induced Bcl-2 expression.
    Aubert N; Falluel-Morel A; Vaudry D; Xifro X; Rodriguez-Alvarez J; Fisch C; de Jouffrey S; Lebigot JF; Fournier A; Vaudry H; Gonzalez BJ
    J Neurochem; 2006 Nov; 99(4):1237-50. PubMed ID: 17026529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
    Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA
    Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.